Skip to main content
Erschienen in: World Journal of Pediatrics 1/2020

16.09.2019 | Original Article

Analysis of clinical manifestations and treatment in 26 children with fibrodysplasia ossificans progressiva in China

verfasst von: Jun-Mei Zhang, Cai-Feng Li, Shuang-Ying Ke, Yu-Rong Piao, Tong-Xin Han, Wei-Ying Kuang, Jiang Wang, Jiang-Hong Deng, Xiao-Hua Tan, Chao Li

Erschienen in: World Journal of Pediatrics | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Fibrodysplasia ossificans progressiva (FOP) is a rare and disabling heritable connective tissue disease that is difficult to treat. This study seeks to explore the clinical characteristics, clinical manifestations, treatment and prognosis of FOP to provide a clinical basis for its early diagnosis and treatment.

Methods

Twenty-six children with FOP were retrospectively analyzed in terms of their onset, clinical manifestations, auxiliary examinations and treatment.

Results

Among the 26 cases, the youngest age of manifestation of mass was 8 days after birth, and the average age was 3 years and 2 months. The peak age was 2–5 years old. Inflammatory mass and toe-finger deformity are the main early clinical manifestations of the disease. These inflammatory masses often lead to hard osteogenic deposits that initially mainly involve the central axis, such as the neck (22/26, 84.6%), back (20/26, 76.9%), and head (13/26, 50%). Toe-finger deformity mainly manifests as symmetrical great toe deformity, or short and deformed thumb and little finger. The diagnosis of FOP requires typical clinical manifestations or ACVR1 gene detection. The main therapeutic drugs for FOP include glucocorticoids and non-steroidal anti-inflammatory drugs. Although not compliant with the recommended medical management of FOP, in our clinical practice children with uncontrollable illness could be treated using a variety of immunosuppressive agents in combination.

Conclusions

FOP is a rare autosomal dominant heritable disease. The main clinical manifestations observed in this study were recurrent inflammatory mass and toe-finger deformity. If the diagnosis and treatment are not performed in a timely manner, serious complications are likely to affect the prognosis. Therefore, early diagnosis and active treatment should be performed.
Literatur
1.
Zurück zum Zitat Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38:525–7.CrossRef Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38:525–7.CrossRef
2.
Zurück zum Zitat Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN. The obligatory role of activin A in the formation of heterotopic bone in fibrodysplasia ossificans progressiva. Bone. 2018;109:210–7.CrossRef Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN. The obligatory role of activin A in the formation of heterotopic bone in fibrodysplasia ossificans progressiva. Bone. 2018;109:210–7.CrossRef
3.
Zurück zum Zitat The medical management of fibrodysplasia ossificans progressive: current treatment considerations International Clinical Consortium on FOP: Philadelphia; 2019. The medical management of fibrodysplasia ossificans progressive: current treatment considerations International Clinical Consortium on FOP: Philadelphia; 2019.
4.
Zurück zum Zitat Illingworth RS. Myositis ossificans progressiva (Munchmeyer's disease). Brief review with report of two cases treated with corticosteroids and observed for 16 years. Arch Dis Child. 1971;46:264–8.CrossRef Illingworth RS. Myositis ossificans progressiva (Munchmeyer's disease). Brief review with report of two cases treated with corticosteroids and observed for 16 years. Arch Dis Child. 1971;46:264–8.CrossRef
5.
Zurück zum Zitat Bocciardi R, Bordo D, Di Duca M, Di Rocco M, Ravazzolo R. Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur J Hum Gent. 2009;17:311–8.CrossRef Bocciardi R, Bordo D, Di Duca M, Di Rocco M, Ravazzolo R. Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur J Hum Gent. 2009;17:311–8.CrossRef
6.
Zurück zum Zitat Furuya H, Ikezoe K, Wang L, Ohyagi Y, Motomura K, Fujii N, et al. A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am J Med Genet A. 2008;146A:459–63.CrossRef Furuya H, Ikezoe K, Wang L, Ohyagi Y, Motomura K, Fujii N, et al. A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am J Med Genet A. 2008;146A:459–63.CrossRef
7.
Zurück zum Zitat Gregson CL, Hollingworth P, Williams M, Petrie KA, Bullock AN, Brown MA, et al. A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Bone. 2011;48:654–8.CrossRef Gregson CL, Hollingworth P, Williams M, Petrie KA, Bullock AN, Brown MA, et al. A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Bone. 2011;48:654–8.CrossRef
8.
Zurück zum Zitat Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30:379–90.CrossRef Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30:379–90.CrossRef
9.
Zurück zum Zitat Whyte MP, Wenkert D, Demertzis JL, DiCarlo EF, Westenberg E, Mumm S. Fibrodysplasia ossificans progressiva: Middle-age onset of heterotopic ossification from a unique missense mutation (c.974G%3eC, p.G325A) in ACVR1. J Bone Miner Res. 2012;27:729–37.CrossRef Whyte MP, Wenkert D, Demertzis JL, DiCarlo EF, Westenberg E, Mumm S. Fibrodysplasia ossificans progressiva: Middle-age onset of heterotopic ossification from a unique missense mutation (c.974G%3eC, p.G325A) in ACVR1. J Bone Miner Res. 2012;27:729–37.CrossRef
10.
Zurück zum Zitat Petrie KA, Lee WH, Bullock AN, Pointon JJ, Smith R, Russell RG, et al. Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PLoS One. 2009;4:e5005.CrossRef Petrie KA, Lee WH, Bullock AN, Pointon JJ, Smith R, Russell RG, et al. Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PLoS One. 2009;4:e5005.CrossRef
11.
Zurück zum Zitat Shore EM, Feldman GJ, Xu M, Kaplan FS. The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab. 2005;3:201–4.CrossRef Shore EM, Feldman GJ, Xu M, Kaplan FS. The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab. 2005;3:201–4.CrossRef
12.
Zurück zum Zitat Zhang W, Zhang K, Song L, Pang J, Ma H, Shore EM, et al. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013;57:386–91.CrossRef Zhang W, Zhang K, Song L, Pang J, Ma H, Shore EM, et al. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013;57:386–91.CrossRef
13.
Zurück zum Zitat Pignolo RJ, Bedford-Gay C, Liljesthröm M, Durbin-Johnson BP, Shore EM, Rocke DM, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31:650–6.CrossRef Pignolo RJ, Bedford-Gay C, Liljesthröm M, Durbin-Johnson BP, Shore EM, Rocke DM, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31:650–6.CrossRef
14.
Zurück zum Zitat Mahboubi S, Glaser DL, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressive. Pediatr Radiol. 2001;31:307–14.CrossRef Mahboubi S, Glaser DL, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressive. Pediatr Radiol. 2001;31:307–14.CrossRef
15.
Zurück zum Zitat Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013;10(Suppl 2):437–48.PubMedPubMedCentral Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013;10(Suppl 2):437–48.PubMedPubMedCentral
16.
Zurück zum Zitat Janoff HB, Zasloff MA, Kaplan FS. Submandibular swelling in patients with fibrodysplasia ossificans progressiva. Otolaryngol Head Neck Surg. 1996;114:599–604.CrossRef Janoff HB, Zasloff MA, Kaplan FS. Submandibular swelling in patients with fibrodysplasia ossificans progressiva. Otolaryngol Head Neck Surg. 1996;114:599–604.CrossRef
17.
Zurück zum Zitat Leavitt BD, Teeples TJ, Viozzi CF. Submandibular space swelling in a patient with fibrodysplasia ossificans progressive: a diagnostic dilemma. J Oral Maxillofac Surg. 2009;67:668–73.CrossRef Leavitt BD, Teeples TJ, Viozzi CF. Submandibular space swelling in a patient with fibrodysplasia ossificans progressive: a diagnostic dilemma. J Oral Maxillofac Surg. 2009;67:668–73.CrossRef
18.
Zurück zum Zitat Lutwak L. Myositis ossificans progressiva. Mineral, metabolic and radioactive calcium studies of the effects of hormones. Am J Med. 1964;37:269–93.CrossRef Lutwak L. Myositis ossificans progressiva. Mineral, metabolic and radioactive calcium studies of the effects of hormones. Am J Med. 1964;37:269–93.CrossRef
19.
Zurück zum Zitat The International Clinical Consortium on FOP. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP. 2011;4:1–100. The International Clinical Consortium on FOP. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP. 2011;4:1–100.
20.
Zurück zum Zitat Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med. 2011;17:454–60.CrossRef Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med. 2011;17:454–60.CrossRef
21.
Zurück zum Zitat Cappato S, Giacopelli F, Ravazzolo R, Bocciardi R. The horizon of a therapy for rare genetic diseases: a “Druggable” future for fibrodysplasia ossificans progressiva. Int J Mol Sci. 2018;19:E989–1007.CrossRef Cappato S, Giacopelli F, Ravazzolo R, Bocciardi R. The horizon of a therapy for rare genetic diseases: a “Druggable” future for fibrodysplasia ossificans progressiva. Int J Mol Sci. 2018;19:E989–1007.CrossRef
Metadaten
Titel
Analysis of clinical manifestations and treatment in 26 children with fibrodysplasia ossificans progressiva in China
verfasst von
Jun-Mei Zhang
Cai-Feng Li
Shuang-Ying Ke
Yu-Rong Piao
Tong-Xin Han
Wei-Ying Kuang
Jiang Wang
Jiang-Hong Deng
Xiao-Hua Tan
Chao Li
Publikationsdatum
16.09.2019
Verlag
Springer Singapore
Erschienen in
World Journal of Pediatrics / Ausgabe 1/2020
Print ISSN: 1708-8569
Elektronische ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-019-00302-x

Weitere Artikel der Ausgabe 1/2020

World Journal of Pediatrics 1/2020 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.